Soluble Thrombomodulin Is Associated With Endothelial Dysfunction Syndromes After Pediatric Hematopoietic Stem Cell Transplantation
Pediatric Blood & Cancer · 2025
DOI: 10.1002/pbc.31675 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2025. Verfasst von Denise Elbæk Horan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics and Adolescent Medicine, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Thrombomodulin, Hematopoietic Stem Cell Transplantation, Graft vs Host Disease, Hepatic Veno-Occlusive Disease. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Childhood Cancer Foundation, Tømrermester Jørgen Holm og Hustru Elisa F. Hansen's Mindelegat, Danish Cancer Society.
Abstract (Originalsprache)
Background
Allogeneic hematopoietic stem cell transplantation (HSCT) is challenged by endothelial dysfunction‐related syndromes like sinusoidal obstruction syndrome (SOS), capillary leak syndrome (CLS), and severe acute graft‐versus‐host disease (aGvHD). We investigated soluble thrombomodulin (sTM), an endothelial damage marker, in relation to endothelial dysfunction syndromes after pediatric HSCT. Procedure We measured sTM levels in 113 children before conditioning until Day +180 after HSCT.
Results
Plasma levels of sTM increased significantly after conditioning, particularly in patients receiving busulfan‐based regimens (Day +7: 5.0 vs. 7.6 ng/mL, p = 0.0023), and remained elevated until Day +180 after HSCT. Children diagnosed with SOS ( n = 51) had significantly higher sTM levels at Days +7 and +14 than children without SOS (Day +7: 7.3 vs. 5.0 ng/mL, p = 0.017). High sTM levels at Day +14 were associated with aGvHD Grade III–IV ( n = 8) in multivariable analysis (OR = 3.0 per quartile increase in sTM, p = 0.021). Likewise, children diagnosed with CLS ( n = 15) displayed higher sTM levels at Day +7 (5.3 vs. 8.0 ng/mL, p = 0.037), while sTM levels were not associated with engraftment syndrome or bacteremia.
Conclusion
High sTM levels early after pediatric HSCT are associated with the development of SOS, CLS, and severe aGvHD. These results suggest that conditioning‐induced endothelial damage and activation of pro‐thrombotic environment play key roles in the pathogenesis of these syndromes, indicating that sTM may prove clinically useful to guide early diagnosis and treatment of endothelial damage syndromes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics and Adolescent Medicine, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
- Institute for Inflammation Research, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
- CAG Center for Endotheliomics, Department of Clinical Immunology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark, Copenhagen, Denmark.
- Institute of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
ORCID-Profile: Denise Elbæk Horan, Katrine Kielsen
Förderung
- Childhood Cancer Foundation
- Tømrermester Jørgen Holm og Hustru Elisa F. Hansen's Mindelegat
- Danish Cancer Society
- Dagmar Marshalls Fond
- Kræftens Bekæmpelse
Zitieren
APA
Horan, D. E., Johansson, P. I., Ifversen, M., Nielsen, C. H., Müller, K., & Kielsen, K. (2025). Soluble Thrombomodulin Is Associated With Endothelial Dysfunction Syndromes After Pediatric Hematopoietic Stem Cell Transplantation. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31675
Vancouver
Horan DE, Johansson PI, Ifversen M, Nielsen CH, Müller K, Kielsen K. Soluble Thrombomodulin Is Associated With Endothelial Dysfunction Syndromes After Pediatric Hematopoietic Stem Cell Transplantation. Pediatric Blood & Cancer. 2025. doi:10.1002/pbc.31675
BibTeX
@article{Horan2025,
author = {Horan, Denise Elbæk and Johansson, Pär I and Ifversen, Marianne and Nielsen, Claus H and Müller, Klaus and Kielsen, Katrine},
title = {Soluble Thrombomodulin Is Associated With Endothelial Dysfunction Syndromes After Pediatric Hematopoietic Stem Cell Transplantation},
journal = {Pediatric Blood & Cancer},
year = {2025},
doi = {10.1002/pbc.31675}
}
EUVIMED